Abeona reports preliminary Q1 cash $62.7M; terminates $106M ATM prospectus

ABEONA THERAPEUTICS INC.

Preliminary cash, equivalents, and investments of $62.7M as of March 31, 2024.
Terminated June 2023 ATM prospectus covering up to $106M in common shares.
No sales under Sales Agreement until a new prospectus or registration statement is filed.
Sales Agreement itself remains in effect; only the specific supplement is suspended.

item 2.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABEONA THERAPEUTICS INC. reported preliminary financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: preliminary results

Exact text from the filing

the Company’s cash, cash equivalents, restricted cash and short-term investments were approximately $62.7 million. This financial information is preliminary and subject to change in connection with the completion of the Company’s financial statements for the quarter ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-017625

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.